IMMagine
Brief summary
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation study up to 28 weeks. The treatment decision for RZB must be made independent of this study enrollment.
Observational study
Age:
18 Years and older.
Inclusion Criteria:
- Confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by
a dermatologist and presence of moderate to severe psoriasis symptoms according to
physician's clinical judgment at the time of recruitment.
- Participants initiating RZB treatment for psoriasis as per local label. Physician's
decision for treatment with risankizumab must have been reached prior to and
independently of recruitment in the study.
- Participants able to understand and communicate with the investigator and comply
with the requirements of the study.
- Willingness and ability to comply with all study requirements.
Exclusion Criteria:
- Current or recent (within the last 30 days) participation in an interventional
clinical trial.
